Travere Therapeutics (TVTX) Equity Average (2011 - 2026)

Travere Therapeutics has reported Equity Average for 16 years, with the latest figure at $106.8 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 132.38% year-over-year to $106.8 million; the trailing twelve-month figure through Mar 2026 stood at $106.8 million (up 132.38% YoY), and the FY2025 full-year result was $87.0 million, down 33.08% from the prior year.
• Equity Average for Q1 2026 stood at $106.8 million, up from $94.2 million in the prior quarter.
• The five-year high for Equity Average was $255.1 million in Q1 2022, with the low at -$7.7 million in Q3 2024.
• Historically, Equity Average has averaged $109.8 million across 5 years, with a median of $106.8 million in 2026.
• Annual changes were most pronounced in 2024 — Equity Average sank 103.86% — and 2025, when it surged 794.53%.
• Travere Therapeutics' Equity Average stood at $71.8 million in 2022, then surged by 234.83% to $240.3 million in 2023, then tumbled by 94.04% to $14.3 million in 2024, then jumped by 558.18% to $94.2 million in 2025, then climbed by 13.36% to $106.8 million in 2026.
• The last three Equity Average figures came in at $106.8 million (Q1 2026), $94.2 million (Q4 2025), and $53.2 million (Q3 2025), per Business Quant data.